Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering.
It is a key post-marketing responsibility of the marketing authorisation holder (MAH) to keep dossiers up to date, and changes must be submitted as variations to the appropriate regulatory authority.
This interactive event will provide an invaluable overview of the EU system for variations, with practical advice on the preparation and submission of variation applications using the various European procedures. The course will cover the latest variation regulations and offer guidance from an industry expert on how to optimise your regulatory procedures to help achieve faster approval. The programme will include filing tips and strategies with information and advice on creating a global dossier and implementation periods.
Practical sessions throughout the two days will provide an opportunity to discuss different scenarios and strategies with other participants.
Benefits of attending:
- Gain an overview of the EU system for variations
- Assess how pharma companies are working in this evolving regulatory environment
- Profit from practical advice on the preparation and submission of variation applications
- Understand the impact of Module 3 on your variations dossier
- Discuss filing tips and strategies to help achieve faster approval
Who Should Attend:
This course will be particularly relevant for those working in registration and regulatory affairs. It will also be of interest to anyone with an involvement in the variations process including QA, clinical safety and pharmacovigilance personnel.
Key Topics Covered:
Day 1
Basis of EU Regulations 1234/2008 and 712/2012
- Classification in accordance with the legislation
- Understand the differences between type lA, type IB and type ll variations
- Clarify foreseen and unforeseen variations
Special topics in variations
- Handling active ingredient master files as variations
- Submission of new clinical data
Practical session: Analysing and classifying the different changes
Grouping and work-sharing
- Understanding when grouping is appropriate
- Clarifying what types of variations may be grouped
- Guidance on assembling a grouped submission
- Understanding when work-sharing is appropriate
Understanding Module 3
- The dossier impact on variations
- QbD
- CQA pyramids
Practical session: Understanding reviewers
Filing strategy
- Creating a global dossier (gold/silver/ bronze versions)
- Understanding implementation and grace periods
- Fixed and rolling implementation strategy
Practical session: Plan the timelines/project management of a variation submission
Day 2
Other procedures
- Article 5
- Urgent safety restrictions
- Understanding when to use extension applications
Submission planning
- Identify and understand strategic considerations
Data requirements for type II variations
- Learn how to identify and support a type II change
Practical session: Data requirements for more complex changes
Variations through national procedures and differences from centralised procedure
- Understand the procedures
- Languages and translations
- Explore the linguistic review process
Mutual recognition and decentralised procedures for variations
- Understand the procedures and responsibilities of the MAH, RMS and CMS
- Learn how to efficiently plan for and run an MR variation procedure
Practical session: A variation to an example MRP authorised product including planning timelines and impact of referrals
Advanced compliance
- Creating your own compliance requirements
- SUPAC guidance
Speakers:
Andrew Willis
Consultant
Independent
Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services. Catalent is the world's leading contract manufacturer and distributor of pharmaceuticals, and he was head of a team of internal and external regulatory affairs consultants. He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He has 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs.
He currently has a total of 28 years pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many Biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.
He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities. Specific experience includes the project management of a large MAA requiring full clinical data, followed by Mutual Recognition of the application in all of the European Concerned Member States. The project recorded successful outcomes in all major markets (26 countries) and was viewed as highly successful by the client, meeting very stringent project timings.
For more information about this conference visit https://www.researchandmarkets.com/r/27sh81
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
